Influence of concurrent medications on outcomes of men with prostate cancer included in the TAX 327 study
- PMID: 23671512
- PMCID: PMC3650799
- DOI: 10.5489/cuaj.267
Influence of concurrent medications on outcomes of men with prostate cancer included in the TAX 327 study
Abstract
Objectives: The TAX 327 trial was pivotal in establishing docetaxel in castration refractory metastatic prostate cancer. Various commonly prescribed and over-the-counter co-administered medications are thought to exhibit anti-neoplastic properties and/or could potentially have pharmacokinectic interactions with docetaxel lessening the effectiveness of chemotherapy.
Methods: To examine the effect of on prostate cancer outcomes within this trial, we examined overall survival, prostate-specific antigen (PSA) response, percent PSA reduction, pain response and QOL responses for 14 families of medications including metformin, digoxin, verapamil, proton pump inhibitors, nitrates, statins, cox-2 inhibitors, warfarin, heparins, ascorbic acid, selenium, tocopherol, antidepressants and erythropoietin.
Results: Our findings did not reveal any medication that had a significant additive or synergistic effect with docetaxel. We did note, however, that patients on digoxin or verapamil had poorer overall survival, possibly due to a trend of fewer cycles of administered chemotherapy being administered to the verapamil group, consistent with a pharmacokinectic interaction.
Conclusions: These data are only hypothesis-generating given the statistical limitations, but may form a basis for similar future analysis in other malignancies. The data suggest the need to be aware of pharmacokinectic interactions with medications that may interact with docetaxel.
Similar articles
-
The Effect of Metformin Use during Docetaxel Chemotherapy on Prostate Cancer Specific and Overall Survival of Diabetic Patients with Castration Resistant Prostate Cancer.J Urol. 2017 Apr;197(4):1068-1075. doi: 10.1016/j.juro.2016.10.069. Epub 2016 Oct 28. J Urol. 2017. PMID: 27984108
-
Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study.Clin Cancer Res. 2008 May 1;14(9):2763-7. doi: 10.1158/1078-0432.CCR-07-0944. Clin Cancer Res. 2008. PMID: 18451243 Clinical Trial.
-
TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer.Health Technol Assess. 2016 Jul;20(53):1-288. doi: 10.3310/hta20530. Health Technol Assess. 2016. PMID: 27434595 Free PMC article. Clinical Trial.
-
Chemotherapy for hormone-refractory prostate cancer.Cochrane Database Syst Rev. 2006 Oct 18;(4):CD005247. doi: 10.1002/14651858.CD005247.pub2. Cochrane Database Syst Rev. 2006. PMID: 17054249 Review.
-
Prostate-Specific Antigen-Based Screening for Prostate Cancer: A Systematic Evidence Review for the U.S. Preventive Services Task Force [Internet].Rockville (MD): Agency for Healthcare Research and Quality (US); 2018 May. Report No.: 17-05229-EF-1. Rockville (MD): Agency for Healthcare Research and Quality (US); 2018 May. Report No.: 17-05229-EF-1. PMID: 30085502 Free Books & Documents. Review.
Cited by
-
Friend or foe? The current epidemiologic evidence on selenium and human cancer risk.J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2013;31(4):305-41. doi: 10.1080/10590501.2013.844757. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2013. PMID: 24171437 Free PMC article. Review.
-
The Prognostic Effect of Statin Use on Urologic Cancers: An Updated Meta-Analysis of 35 Observational Studies.Medicine (Baltimore). 2015 Sep;94(36):e1523. doi: 10.1097/MD.0000000000001523. Medicine (Baltimore). 2015. PMID: 26356727 Free PMC article.
-
The Effects of Statins on Prostate Cancer Patients Receiving Androgen Deprivation Therapy or Definitive Therapy: A Systematic Review and Meta-Analysis.Pharmaceuticals (Basel). 2022 Jan 22;15(2):131. doi: 10.3390/ph15020131. Pharmaceuticals (Basel). 2022. PMID: 35215243 Free PMC article. Review.
-
Association between baseline body mass index and survival in men with metastatic hormone-sensitive prostate cancer: ECOG-ACRIN CHAARTED E3805.Prostate. 2022 Sep;82(12):1176-1185. doi: 10.1002/pros.24369. Epub 2022 May 10. Prostate. 2022. PMID: 35538398 Free PMC article. Clinical Trial.
-
Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders.Cancer Prev Res (Phila). 2014 Sep;7(9):867-85. doi: 10.1158/1940-6207.CAPR-13-0424. Epub 2014 Jul 1. Cancer Prev Res (Phila). 2014. PMID: 24985407 Free PMC article. Review.
References
-
- Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502–12. - PubMed
-
- Berthold DR, Pond GR, Soban F, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol. 2008;26:242–5. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous